Revance Therapeutics (RVNC) Tops Q3 EPS by 25c

Revance Therapeutics (NASDAQ: RVNC) reported Q3 EPS of ($0.64), $0.25 better than the analyst estimate of ($0.89). Revenue for the quarter came in at $75 thousand versus the consensus estimate of $70 thousand.

For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Nike names former Pfizer CFO David Denton as new finance chief
• KeyBanc Upgrades Nucor (NUE) to Overweight